- Home
- ZNTL vs NMRA Comparison
ZNTL vs NMRA Comparison
Compare ZNTL & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZNTL | NMRA |
|---|---|---|
| Founded | 2014 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 468.9M | 554.0M |
| IPO Year | 2020 | 2023 |
Fundamental Metrics
Financial Performance| Metric | ZNTL | NMRA |
|---|---|---|
| Price | $3.92 | $2.24 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 8 |
| Target Price | $6.60 | ★ $7.50 |
| AVG Volume (30 Days) | ★ 4.2M | 1.4M |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.03 | 5.23 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.13 | $0.63 |
| 52 Week High | $6.95 | $3.65 |
Technical Indicators
Market Signals| Indicator | ZNTL | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 52.33 | 46.79 |
| Support Level | $1.53 | $1.79 |
| Resistance Level | $3.95 | $2.58 |
| Average True Range (ATR) | 0.77 | 0.17 |
| MACD | -0.08 | 0.05 |
| Stochastic Oscillator | 30.87 | 55.00 |
Price Performance
Historical ComparisonAbout ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.